Introduction: Gestational trophoblastic disease (GTD) consists of group of disorders having pathology of abnormal trophoblastic proliferation ranging from hydatidiform mole to gestational trophoblastic neoplasia. Based on differences in morphology, histopathology, karyotype and clinical features, hydatidiform mole can be categorized into partial and complete moles. Molar pregnancy incidence var...

Gestational trophoblastic disease (GTD) is a rare but curable disease. Recent improvements in diagnosis and molecular biology have resulted in changes in staging and treatment. These guidelines provide evidence-based recommendation on how to manage GTD.

Gestational trophoblastic neoplasia (GTN) includes the abnormal pregnancies complete (CHM) and partial hydatidiform mole (PHM) and the malignant gestational trophoblastic tumours (GTT) invasive mole (IM), choriocarcinoma, placental site trophoblastic tumour (PSTT) and epithelioid trophoblastic tumour (ETT). While many genetic studies have been performed in both CHM and PHM, similar studies of t...

Gestational trophoblastic disease is a spectrum of placental disorders ranging from benign molar pregnancies to the neoplastic conditions such as invasive mole and choriocarcinoma. These patients are identified early due to markedly elevated hCG levels and characteristic ultrasound findings. Uterine evacuation is the recommended treatment, while chemotherapy can be reserved for patients with re...

AIMS To investigate the pattern of telomerase activity in hydatidiform mole as compared with normal placenta and choriocarcinoma, and to determine the prognostic significance of telomerase activity in hydatidiform mole. METHODS Telomerase activity in 35 cases of hydatidiform mole, 35 normal placentas, one choriocarcinoma sample, and two choriocarcinoma cell lines (JAR, JEG3) was determined us...

BACKGROUND Gestational trophoblastic disease refers to a spectrum of rare benign and malignant gynecologic disorders whose pathogenesis is not well understood. Recent studies from China and the United States have raised the hypothesis that long-term use of oral contraceptives before conception may increase the risk of gestational trophoblastic tumors. A multicenter case-control study of gestati...

BACKGROUND Gestational Trophoblastic Disease (GTD) is a heterogeneous group of diseases that includes partial and complete hydatidiform mole, invasive mole, choriocarcinoma and placental site trophoblastic tumour. The incidence of GTD varies in different parts of the world. The malignant potential of this disease is higher in South East Asia in comparison to western countries. Objectives of stu...

a Department of Obstetrics and Gynecology, University of Hong Kong, Queen Mary Hospital, Hong Kong, China b Departments of Histopathology and Medical Oncology, Charing Cross Trophoblastic Disease Center, Charing Cross campus of Imperial College London, London, UK c Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institu...

Gestational trophoblastic disease has been reported to be responsive to chemotherapy, with a 90% cure rate. Several factors place patients at high risk of experiencing treatment failure with single agent chemotherapy. Choriocarcinoma following term pregnancy is very rare and associated with a poor prognosis and a mortality rate of 33-40%. We present a rare case of cutaneous metastasis of chorio...

Gestational trophoblastic neoplasia (GTN) includes the abnormal pregnancies complete (CHM) and partial hydatidiform mole (PHM) and the malignant gestational trophoblastic tumours (GTT) invasive mole (IM), choriocarcinoma, placental site trophoblastic tumour (PSTT) and epithelioid trophoblastic tumour (ETT). While many genetic studies have been performed in both CHM and PHM, similar studies of t...